Loading stock data…
$2.99-0.03 (-0.99%)
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
Whitehawk Therapeutics, Inc. in the Healthcare sector is trading at $3.01 with a market capitalization of $232M. Wall Street consensus targets $7.71 (7 analysts), implying a +156.3% move over the next 12 months. The stock is currently 45% below its 52-week high of $5.50, remaining 20.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$18.11M↑ | -$23.52M↑ | -$24.89M↓ | -$19.55M↑ | -$54.75M |
| Net Income | -$16.64M↑ | -$22.19M↑ | -$23.25M↓ | -$17.75M↑ | -$52.62M |
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The ...